Key clinical point: Zoledronate after denosumab discontinuation prevented the complete return of bone mineral density to baseline levels.

Major finding: Women with osteoporosis who received a single infusion of zoledronate after discontinuing denosumab retained 66% of bone mineral density gains at the lumbar spine, 49% at the total hip, and 57% at the femoral neck.

Study details: The data come from a review of 120 women with postmenopausal osteoporosis who received three or more injections of 60 mg denosumab administered at 6-month intervals over 2-5 years, followed by a single infusion of 5 mg zoledronate 6 months after the final denosumab injection.

Disclosures: The study was funded by OsteoRheuma Bern. The researchers reported having no financial conflicts.